Immunovant Inc IMVT 深 沪
已收盘 04-02 16:00:00 美东时间
24.50
-0.600
-2.39%
华盛通- 最 高25.37
- 今 开23.76
- 成交量 202.50万股
- 最 低 23.24
- 昨 收 25.10
- 总市值 49.87亿
- 52周最高 29.25
- 市盈率 静 --
- 换手率 0.99%
- 52周最低 13.36
- 委 比 97.45%
- 总股本 2.04亿
- 历史最高 53.75
- 量 比 1.73
- 振 幅 8.49%
- 历史最低 3.145
- 每 手 1
- 风险率 4.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BUZZ-U.S. STOCKS ON THE MOVE-Globalstar, Wingstop, US energy stocks
BUZZ-U.S. STOCKS ON THE MOVE-Globalstar, Wingstop, US energy stocks Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 April 2 (Reuters) - Futures tracking Wall Street's main indexe
04-02 19:36
Market-Moving News for April 2nd
GSAT: 24% | Globalstar shares are trading higher following reports suggesting that Amazon is in discussions to acquire the company. IMVT: -17% | Immunovant shares are trading lower after the company
04-02 19:17
UPDATE 1-Immunovant's treatment for eye disease fails late-stage trials
UPDATE 1-Immunovant's treatment for eye disease fails late-stage trials Adds shares, details in paragraph 3-4 April 2 (Reuters) - Immunovant IMVT.O said on Thursday that its therapy to treat a type of eye disease failed to meet the main goals in two late-stage studies. Shares of the company were dow
04-02 17:24
Immunovant's Phase 3 Batoclimab Studies Each Fail To Meet Primary Proptosis Responder Rate Endpoint In Thyroid Eye Disease
Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated greater levels of
04-02 17:08
CORRECTED-Immunovant's treatment for eye disease fails late-stage trials
CORRECTED-Immunovant's treatment for eye disease fails late-stage trials Corrects to say therapy failed in two trials, not one April 2 (Reuters) - Immunovant IMVT.O said on Thursday that its therapy to treat a type of eye disease failed to meet the main goals in two late-stage studies. (Reporting by
04-02 17:04
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Immunovant reported that its Phase 3 studies of batoclimab for thyroid eye disease (TED) did not meet the primary endpoint of achieving a ≥2mm proptosis reduction at Week 24. However, patients saw greater improvement during the initial high-dose period than during the subsequent low-dose period, suggesting benefits of deeper IgG suppression. Hyperthyroid patients showed similar thyroid hormone normalization rates as seen in the Phase 2 Graves’ di...
04-02 09:00
Roivant President and Immunovant CEO Eric Venker Disposes of Roivant Sciences Common Shares
Roivant President and Immunovant CEO Eric Venker Disposes of Roivant Sciences Common Shares Eric Venker, President & Immunovant CEO, reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public
02-19 06:57
美股大行评级 | 安森美半导体获多家大行调目标价；BD医疗、Dynatrace、Monday、Regenxbio遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持内克塔治疗"买入"评级，目标价从135美元升至165美元；BTIG：维持内克塔治疗"买入"评级，目标价从118美元升至151美元
02-11 11:02
美股大行评级 | 生化基因(BIIB)获10家大行上调目标价！Hims & Hers Health遭花旗下调目标价从30美元降至16.5美元
今日重点评级关注：瑞杰金融：上调Lumexa Imaging Holdings评级至"强力买入"，目标价23美元；BTIG：维持Transocean"买入"评级，目标价从6美元升至10美元
02-10 10:29
Immunovant Rides Brepocitinib Momentum Into 2026
Immunovant, Inc. (($IMVT)) has held its Q3 earnings call. Read on for the main ...
02-10 08:20
